

Wednesday, October 26

Nagano

Session 6: Payloads and Mechanisms of Action

Chairpersons: Grant McFadden, Kazunori Aoki

-
- 8:30-8:45** **INV19: Kazunori Aoki**
National Cancer Center Research Institute, Japan
 Development of Oncolytic Adenoviruses Targeting Advanced Pancreatic Carcinoma
-
- 8:45-9:00** **Oral 13: Steve H Thorne**
Kalivir Immunotherapeutics, USA
 A novel oncolytic virotherapy, VET3-TGI, displays potent therapeutic activity in multiple mouse tumor models through blocking TGF-beta and augmenting type-1 immune response
-
- 9:00-9:15** **Oral 14: Ugo Hirigoyen**
INSERM Nantes University, France
 Characterization of tumor extracellular vesicles produced during oncolytic infection
-
- 9:15-9:30** **Oral 15: Michael C Brown**
Duke University Medical School, Durham, NC, USA
 Intratumor polio vaccine-specific CD4+ T cell recall coordinates antitumor type I and II immunity during polio virotherapy
-
- 9:30-9:45** **Oral 16: Louisa S Chard Dunmall**
Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, UK
 Intravenous delivery of Vaccinia virus expressing interleukin-21 in combination with immune checkpoint inhibition is an effective treatment for glioblastoma
-
- 9:45-10:00** **Oral 17: Jianhua Yu**
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.
 Specific targeting of glioblastoma with an oncolytic virus expressing a Cetuximab-CCL5 fusion protein induces both innate and adaptive anti-tumor immunity
-
- 10:00-10:15** **Oral 18: Tacien Petithomme**
CRCI2NA, Inserm, LabEx IGO, Nantes University, France
 Novel chimeric proteins as immunoactivating transgenes for oncolytic immunotherapy
-
- 10:15-10:45** **Coffee Break**



Program

Wednesday, October 26

Nagano

Keynote Lecture 2

Chairperson: Kerry Fisher

10:45-11:45

INV20: Marta M Alonso

Dpt. Of Pediatrics, Navarra University Clinic, Pamplona, Spain

Translating the Delta-24 Oncolytic Adenovirus Platform for Pediatric Brain Tumors

Sponsored by Replimune

12:15-13:15

Lunch (provided)

Wednesday, October 26

Nagano

Session 7: Combination Therapies

Chairpersons: Kerry Fisher, Norimitsu Kadowaki

13:30-13:55

INV21: Kerry Fisher

University of Oxford, UK

Targeting tumour stroma with oncolytic viruses

13:55-14:10

INV22: Norimitsu Kadowaki

Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa

Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms

14:10-14:25

INV23: Mikihiro Nakamori

Division of Digestive Surgery, Osaka Minami Medical Center, National Hospital Organization

Therapeutic development of oncolytic herpes viruses for advanced gastric cancer

14:25-14:40

Oral 19: Richard Baugh

University of Oxford, UK

Targeting stress-associated ligands in glioblastoma with a bispecific T cell engager synergises with conventional therapy and enhances oncolytic virotherapy

14:40-14:55

Oral 20: Candelaria Gomez-Manzano

MD Anderson Cancer Center, Houston, TX, USA

Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD

Wednesday, October 26

Nagano

Afternoon Session 2

Chairperson: Kenzaburo Tani

15:05-16:05 INV24: Makoto Yamagishi *No on-demand

*Department of Computational Biology and Medical Sciences,
Graduate School of Frontier Sciences, The University of Tokyo, Japan*

Overall Picture of Genetic and Epigenetic Characteristics in HTLV-1-Associated Diseases

Sponsored by Daiichi Sankyo Co., Ltd.

16:05-16:35 Break

Wednesday, October 26

Nagano

Session 8: Novel Viral Platforms

Chairpersons: Noriyuki Kasahara, Hideki Kasuya

16:35-17:00 INV25: Noriyuki Kasahara

University of California San Francisco, USA

17:00-17:15 INV26: Hideki Kasuya

Nagoya University, Japan

The novel armed oncolytic HSV exhibits a strong antitumor effect that completely regresses tumors

17:15-17:30 INV27: Kenzaburo Tani

Laboratory of ALA-Advanced Medical Research, Institute for Quantitative Biosciences, The University of Tokyo, Japan

Preclinical studies of Coxsackieviruses as new oncolytic virus

17:30-17:45 Oral 21: Eriko Matsuda

*Department of Gene Therapy and Regenerative Medicine, Kagoshima University
Graduate School of Medical and Dental Sciences, Japan*

Development of a method using oncolytic adenovirus to specifically eliminate tumorigenic cells in pluripotent stem cell-based regenerative medicine

17:45-18:00 Oral 22: Ahmet Hazini

Department of Oncology, University of Oxford, UK

Promoting improved agnostic cross presentation of tumour antigens with an oncolytic adenovirus expressing RIPR-SIRPa

Wednesday, October 26

Asama

19:00-21:00 Farewell Dinner